BioNTech Total Assets from 2010 to 2024

BNTX Stock  USD 87.89  1.41  1.63%   
BioNTech Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals
 
Total Assets  
First Reported
2018-12-31
Previous Quarter
22.2 B
Current Value
23 B
Quarterly Volatility
9.9 B
 
Covid
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many exotic indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0113 or PTB Ratio of 1.19. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
This module can also supplement BioNTech's financial leverage analysis and stock options assessment as well as various BioNTech Technical models . Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Total Assets Growth Pattern

Below is the plot of the Total Assets of BioNTech SE over the last few years. Total assets refers to the total amount of BioNTech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BioNTech SE books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. BioNTech's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 23.01 B10 Years Trend
Slightly volatile
   Total Assets   
       Timeline  

BioNTech Total Assets Regression Statistics

Arithmetic Mean6,209,766,267
Geometric Mean1,381,259,143
Coefficient Of Variation157.23
Mean Deviation8,191,166,658
Median389,959,000
Standard Deviation9,763,591,893
Sample Variance95327726.7T
Range23.8B
R-Value0.79
Mean Square Error38001571.2T
R-Squared0.63
Significance0.0004
Slope1,732,636,046
Total Sum of Squares1334588173.2T

BioNTech Total Assets History

202424.2 B
202323 B
202223.3 B
202115.8 B
20202.3 B
2019797.6 M
2018653 M

Other Fundumenentals of BioNTech SE

BioNTech Total Assets component correlations

1.00.62-0.930.990.940.690.820.760.860.751.00.580.810.671.01.00.86
1.00.62-0.951.00.950.650.830.780.840.780.990.530.830.661.01.00.85
0.620.62-0.530.60.80.270.790.740.490.720.590.330.780.720.620.60.85
-0.93-0.95-0.53-0.95-0.88-0.44-0.78-0.72-0.69-0.74-0.92-0.26-0.77-0.58-0.94-0.94-0.78
0.991.00.6-0.950.950.610.850.80.810.80.990.490.840.621.00.990.83
0.940.950.8-0.880.950.50.940.90.730.890.920.460.940.710.950.930.89
0.690.650.27-0.440.610.50.250.170.920.150.720.950.250.520.650.680.55
0.820.830.79-0.780.850.940.250.990.510.990.780.260.990.540.830.80.8
0.760.780.74-0.720.80.90.170.990.431.00.710.190.990.460.770.740.73
0.860.840.49-0.690.810.730.920.510.430.410.890.850.50.670.840.860.77
0.750.780.72-0.740.80.890.150.991.00.410.710.160.990.450.770.740.71
1.00.990.59-0.920.990.920.720.780.710.890.710.60.770.660.991.00.84
0.580.530.33-0.260.490.460.950.260.190.850.160.60.260.520.540.560.51
0.810.830.78-0.770.840.940.250.990.990.50.990.770.260.590.830.790.79
0.670.660.72-0.580.620.710.520.540.460.670.450.660.520.590.660.660.84
1.01.00.62-0.941.00.950.650.830.770.840.770.990.540.830.661.00.86
1.01.00.6-0.940.990.930.680.80.740.860.741.00.560.790.661.00.85
0.860.850.85-0.780.830.890.550.80.730.770.710.840.510.790.840.860.85
Click cells to compare fundamentals

About BioNTech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include BioNTech income statement, its balance sheet, and the statement of cash flows. BioNTech investors use historical funamental indicators, such as BioNTech's Total Assets, to determine how well the company is positioned to perform in the future. Although BioNTech investors may use each financial statement separately, they are all related. The changes in BioNTech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioNTech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BioNTech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Assets23 B24.2 B
Intangibles To Total Assets 0.05  0.09 

BioNTech Investors Sentiment

The influence of BioNTech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioNTech. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioNTech's public news can be used to forecast risks associated with an investment in BioNTech. The trend in average sentiment can be used to explain how an investor holding BioNTech can time the market purely based on public headlines and social activities around BioNTech SE. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioNTech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioNTech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioNTech's news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioNTech.

BioNTech Implied Volatility

    
  48.79  
BioNTech's implied volatility exposes the market's sentiment of BioNTech SE stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if BioNTech's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that BioNTech stock will not fluctuate a lot when BioNTech's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioNTech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioNTech's short interest history, or implied volatility extrapolated from BioNTech options trading.

Pair Trading with BioNTech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.

Moving together with BioNTech Stock

  0.66VRTX Vertex Pharmaceuticals Financial Report 6th of May 2024 PairCorr

Moving against BioNTech Stock

  0.68NVO Novo Nordisk AS Financial Report 2nd of May 2024 PairCorr
  0.67RZLT Rezolute TrendingPairCorr
  0.66MRK Merck Company Report 25th of April 2024 PairCorr
  0.6CELC Celcuity LLC Financial Report 20th of May 2024 PairCorr
  0.59EWTX Edgewise Therapeutics Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:
Check out the analysis of BioNTech Correlation against competitors.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for BioNTech Stock analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.80)
Earnings Share
4.12
Revenue Per Share
15.873
Quarterly Revenue Growth
(0.65)
Return On Assets
0.0262
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.